Comparative study of Lumbrokinase and Alprostadil Injection in treatment of diabetic nephropathy

Objective To compare the clinical efficacy of Lumbrokinase and Alprostadil Injection in treatment of diabetic nephropathy, and to provide the reference for clinical treatment. Methods 100 patients with diabetic nephropathy were selected in our hospital. They were randomly divided into observation group and control group with 50 cases in each. In the observation group based on routine treatment combined with Lumbrokinase capsules for treatment, the control group on the basis of conventional therapy plus Alprostadil Injection intravenous infusion therapy. Urea nitrogen before and after 4 weeks of treatment, compared two groups of patients(BUN), creatinine(SCr) and detection of 24 hour urinary protein quantitative results, and observe the adverse reactions of the two groups of patients in the process of occurrence. Results After treatment,the observation group BUN level was(7.92±5.37) mmol/L,SCr level was(87.46±37.29) μ mol/L,24 hour urinary protein quantitative level was(191.39±69.27) Mg, the whole blood viscosity at low shear level was(5.28±1.96) CP, fibrinogen level was(3.02±0.27) g/L. control group BUN level(8.53± 4.38) mmol/L, SCrlevel was(89.19± 35.31) μ mol/L, 24 hour urinary protein quantitative level was(181.36±64.16) Mg, the whole blood viscosity at low shear levelwas(5.36±1.73) CP, fibrinogen level was(3.06±0.35) g/L. Two groups of patients after the 24 hour urinary protein quantity, blood viscosity of low shear, fibrinogen test results were significantly lower than that before treatment(P 0.05), the observation group after treatment BUN wassignificantly lower than that before treatment(P 0.05), the twogroups after treatment BUN, SCr, 24hours urine proteinthe comparison of the whole blood viscosity, low shear, the fiber limiting proteinexamination results, the differences were not statistically significant(P0.05); the twogroups of patients during treatment were not seriousadverse reactions. Conclusion Lumbrokinase capsules can effectively reduce the proteinuria in diabetic nephropathy patients, improve the curative effect of diabetic nephropathy, which is convenient to take, it is worthy of clinical application.